Fulcrum Therapeutics(FULC) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 ― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., – November 13, 2024 – Fulcrum Therapeutics, Inc. ...